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Abstract
Introduction. Marfan syndrome is a hereditary connective tissue disorder caused by impaired synthesis of a fibrillin 
protein. This results in a broad spectrum of clinical manifestations, in particular cardiovascular, skeletal and ocular 
features. Marfanoid phenotype is defined as manifesting some features of Marfan syndrome, but not fulfilling the 
criteria of the diagnosis. Abnormal synthesis of the fibrillin is the reason of impairment of elastic fibers. This effects in 
increasing arterial stiffness, which can be characterized by pulse wave velocity (PWV) and augmentation index (AI).
Material and methods. Study included 72 patients suspected of Marfan syndrome. On the basis of modified Ghent 
criteria they were divided into two groups: 37 patients were diagnosed with Marfan syndrome and 35 patients were 
classified as marfanoid phenotype. Research included also 36 healthy controls. PWV and AI values were obtained 
by applanation tonometry method. 
Results. Mean PWV is higher in Marfan syndrome rather than marfanoid phenotype and healthy controls. The 
lowest mean value of PWV was found among patients with marfanoid phenotype. The highest mean AI value was 
presented in Marfan syndrome. The lowest mean AI was obtained in a group with marfanoid phenotype.
Conclusions. Patients with Marfan syndrome are presenting higher values of PWV and AI than patients with 
marfanoid phenotype or healthy controls. The lowest values of PWV and AI were obtained among patients with 
marfanoid phenotype. Patients like these are taller than the others, however, their arterial walls most likely have 
correct structure, which causes beneficial hemodynamic conditions.
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Streszczenie
Wstęp. Zespół Marfana jest uwarunkowaną genetycznie chorobą tkanki łącznej spowodowaną nieprawidłową 
syntezą białka fibryliny. U  chorych występuje wiele objawów klinicznych, zwłaszcza wiązanych z układem ser-
cowo-naczyniowym, szkieletem i  narządem wzroku. Fenotyp marfanoidalny definiuje się jako występowanie 
niektórych cech zespołu Marfana, jednak niespełniających kryteriów rozpoznania tego zespołu. Nieprawidłowa 
synteza fibryliny powoduje zaburzenia struktury włókien elastycznych. To prowadzi do zwiększenia sztywności 
tętnic, którą można mierzyć za pomocą szybkości fali tętna (PWV, pulse wave velocity) i wskaźnika wzmocnienia 
(AI, augmentation index).
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Materiał i  metody. Do badania włączono 72 chorych z  podejrzeniem zespołu Marfana. Na podstawie zmody-
fikowanych kryteriów Ghenta chorych podzielono na dwie grupy: u 37 osób rozpoznano zespół Marfana, a u 35 
stwierdzono fenotyp marfanoidalny. W badaniu uwzględniono ponadto grupę kontrolną złożoną z 36 zdrowych 
osób. Wartości PWV i AI uzyskano metodą tonometrii aplanacyjnej.
Wyniki. Średnia wartość PWV była wyższa u osób z zespołem Marfana niż w grupie z fenotypem marfanoidalnym 
i w grupie kontrolnej. Najniższą wartość PWV stwierdzono u osób z fenotypem marfanoidalnym. Najwyższą średnią 
wartością AI cechowała się grupa z zespołem Marfana, natomiast najniższą — osoby z fenotypem marfanoidalnym.
Wnioski. U chorych z zespołem Marfana wartości PWV i AI były wyższe niż u osób z fenotypem marfanoidalnym 
i zdrowych osób z grupy kontrolnej. Najniższe wartości PWV i AI stwierdzono u osób z fenotypem marfanoidalnym. 
Chorzy ci są wyżsi niż pozostali, jednak w ich przypadku ściany tętnic mają zwykle prawidłową budowę, co zapewnia 
korzystne warunki hemodynamiczne.
Słowa kluczowe: zespół Marfana, fenotyp marfanoidalny, sztywność tętnic, szybkość fali tętna, wskaźnik wzmoc-
nienia, tonometria aplanacyjna
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Introduction
Marfan syndrome is an autosomal dominant con-
nective tissue disorder. In most cases it is caused by 
a mutation of fibrillin 1, a protein which is essential 
for the formation of elastic fibers [1–3]. It appears 
4–6 times per 100 000 cases, usually in families 
[4]. In consequence of the mutation various clinical 
manifestations are present, primarily skeletal, car-
diovascular and ocular [1, 3]. Characteristic feature 
of this syndrome is the wide spectrum of phenotypic 
changes [2]. The relationship between the type of 
mutation and clinical phenotype has been demon-
strated [2, 4]. In this research, marfanoid pheno-
type was defined as a  clinical circumstance where 
a  patient presents some of the Marfan symptoms, 
however he does not fulfill the criteria needed to 
proper diagnosis [2].
Alteration in organisation of the elastin fibers, 
apart from resulting in characteristic clinical features, 
causes changes in the structure of arterial walls. Rep-
resentative image of this is a damage of those fibers 
in intima media while the mucopolysacharides are 
deposited in their place, which contributes to the 
reduction of arterial wall susceptibility and thus to 
the increase of their stiffness [3, 5–8]. This applies 
in particular to the elastic arteries- the aorta and its 
major branches. The impairment of the vascular wall 
increases the probability of pathological dilation of 
the arteries and the most serious complications of 
Marfan syndrome — aortic aneurysm or aortic dis-
section [9].
Applanation tonometry is a method of pulse wave 
analysis. It provides information about pulse wave 
velocity (PWV) and augmentation index (AI). These 
are the parameters that characterize arterial stiffness 
[10–13]. This method enables the estimation of the 
pressure in the aorta (central pressure) and analysis 
of the pressure curve exerted on the arterial wall. 
[12, 14] Increase of the arterial stiffness results in an 
increase in pulse wave propagation velocity. The im-
portance of PWV measure for cardiovascular risk as-
sessment has been previously demonstrated [10, 12, 
14, 15]. The feature that implements those processes 
is the event of reflected wave of pressure spreading to 
peripheral vascular bed and its return to heart. This 
reflected wave begins in places of division of arteries. 
In proper conditions, the reflected wave returns to 
the heart during diastole, which increases diastolic 
blood pressure and improves coronary flow. In case 
of increased arterial stiffness, the return of reflected 
wave occurs too quickly — at the time of contrac-
tion. This results in an increase in systolic central 
blood pressure and pulse pressure (PP) thus the dif-
ference between systolic and diastolic blood pressure 
[10, 14]. The above described mechanism leads to 
development of hypertension. The lack of physiologi-
cal coronary flow during diastole is also an important 
part of this phenomenon. A factor that characterizes 
the degree of increase in the aortic pressure during 
systole is the augmentation index [12, 14, 16]. It is 
defined as quotient of gain factor (difference between 
pressure created by heart in the moment of systole 
and actual pressure in the aorta) to the pressure in 
aorta. It assumes positive values in case of increased 
arterial stiffness, when the reflected wave increases 
central systolic pressure. Negative values represent 
the physiological situation and therefore the return 
of the reflected wave at diastole [12, 14].
Increased arterial stiffness in Marfan syndrome 
was previously demonstrated [3, 5–9, 11, 17, 18]. 
It is also essential to evaluate the occurrence of 
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increased arterial stiffness in patients who do not 
fulfill all diagnostic criteria for Marfan syndrome, 
but absorb clinician attention due to characteristic 
phenotype. It is not excluded that such patients also 
have an increased risk of cardiovascular disease. 
The aim of the study was to assess arterial stiffness 
in patients with Marfan syndrome and marfanoid 
phenotype.
Material and methods
The study included 76 patients aged 6 to 64 years, 
referring to the clinic with suspicion of Marfan syn-
drome. All of the patients gave conscious written 
consent to take part in this research. In order to make 
a correct diagnosis, they have been examined on diffe-
rent specific spheres. Each patient was subjected to car-
diological, orthopedic and ophthalmic examination 
taking into account modified Ghent from 2010 [19]. 
The patients were divided into two groups — pa-
tients who met criteria were diagnosed with Marfan 
syndrome (40 patients) and the remaining patients 
were classified as patients with marfanoid phenotype 
(36 patients).
PWV analysis excluded patients with ventricular 
(3 patients) and supraventricular (1 patient) arrhyth-
mias. Finally, 37 patients with Marfan syndrome and 
35 patients with marfanoid phenotype were included 
in the analysis. 36 healthy subjects were also included 
in the research as a control group (Table I). 
Blood pressure measurement 
The examination was performed after a 5-minute 
rest in a sitting position. Initially, the blood pressure 
was measured by sphygmomanometer. Measure-
ments were made twice on each arm at 1–2 minute 
intervals. Values obtained from each upper limb were 
averaged. As a  final value, the highest from upon 
average values was assumed (Table II).
Measurement of pulse wave velocity  
and central pressure 
After measuring the peripheral pressure, the PWV 
was measured. The examination was performed in 
the same room where the patient was lying on his 
back. The COMPLIOR® sensors were located in 
the place of the most perceptible pulse over the 
carotid and femoral arteries. The distance between 
the sensors was measured with measuring tape. 
After registering a  sufficient number of heart cy-
cles, registration was stopped. For pulse waveform 
analysis, COMPLIOR® System V1.9 was used. The 
system calculated the PWV value based on the 
distance between the sensors and the time needed 
to move the pulse wave between them. In this way, 
a  total of three PWV measurements were made. 
In each measurement, the position of the sensors 
remained unchanged. Therefore, the time needed 
to move the pulse wave was the discriminating 
parameter. From the obtained values, the mean 
PWV was calculated for each patient group based 
on the formula:
(PWV1 + PWV2 + PWV3) / 3 = PWVmean
COMPLIOR® Analyse software at the time pro-
vides information about central pressure. It is count-
ed on the bases of analyses of pulse wave from the 
carotid sensor. Al index (amplification index) was 
used in the research, on the bases of central pres-
sure. Measurement of PWV and AI was made by 4 
researchers.
Statistical analyses 
Studied parameters were presented as average values 
± standard deviation. The importance of differences 
between each group was measured by U-Mann-Whit-
ney test. Statistically important values were estimated 
to be p < 0.05. Statistical analyses were made in STA-
TISTICA 12.5 software.
Table I. Subject characteristic
Marfan syndrome Marfanoid phenotype Control group
Number of patients 37 35 36
Women 16 (43%) 18 (51%) 21 (58%)
Men 21 (57%) 17 (49%) 15 (42%)
Age (years) 25 ± 14 19 ± 8 22 ± 6
Height [cm] 176 ± 18 175 ± 14 173  ± 15
Weight [kg] 63.70 ± 19.40 56.39 ± 15.14 77.49 ± 38.66
BMI 20.14 ± 5.62 18.19 ± 3.45 26.25 ± 13.01
BMI — body mass index
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Table II. Peripheral blood pressure in each group
Marfan syndrome Marfanoid phenotype Control group
SBP [mm Hg] 120 ± 15 113 ± 12 119 ± 13
DBP [mm Hg] 74 ± 11 68 ± 7 74 ± 8
PP [mm Hg] 52 ± 31 44 ± 10 45 ± 13
MAP [mm Hg] 89 ± 11 83 ± 8 89 ± 8
SBP — systolic blood pressure, DBP — diastolic blood pressure, PP — pulse pressure, MAP — mean arterial pressure
Table III. Pulse wave velocity in each group
Marfan syndrome Marfanoid phenotype Control group
PWV [m/s] 6.34 ± 1.76 5.54 ± 1.31 6.02 ± 3.56
Range [m/s] 4.00–12.47 3.50–10.73 3.50–18.10
Median value 6.25 5.53 5.63
PWV — pulse wave velocity
Results
The results of PWV measurements were showed in 
Table III. Statistically significant difference in the va - 
lue of PWV was found between the groups of patients 
with Marfan syndrome and patients with marfanoid 
phenotype. The referential value of PWV according 
to European Society of Hypertension was exceed-
ed by 2 (5.4%) patients in a  group with Marfan 
syndrome, 2 (5.7%) patients in a group with mar-
fanoid phenotype and 3 (8.3%) patients in a control 
group. Because of low average age in all of studied 
groups, another reference value was taken into ac-
count, according to data published in 2015 [10]. It 
equals 6.2 m/s for patients aged less than 30 years 
old. This value was exceeded by 19 (51.4%) pa-
tients in a group with Marfan syndrome, 11 (31.4%) 
Table IV. P values for PWV results in each group
Marfan syndrome Marfanoid phenotype Control group
Marfan syndrome — 0.0110 NS
Marfanoid phenotype 0.0110 — NS
Control group NS NS —
NS — non significant
Table V. Augmentation index values in each group
Marfan syndrome Marfanoid phenotype Control group
AI (%) –4.49 ± 23.53 –19.60 ± 25.45 –18.22 ±17.22
Range (–54.2)–63.06 (–63.33) –66.41 (–48,6) –21.03
Median value –3.42 –19.61 –21.57
AI > 0 (number of patients) 14 (37.8%) 5 (14.3%) 7 (19.4%) 
AI — augmentation index
patients in a group with marfanoid phenotype and 
14 (38.9%) patients in a control group (Table IV).
The highest median value of PWV was present-
ed between patients with Marfan syndrome, lowest 
one between patients with marfanoid phenotype. In 
Marfan group was obtained the narrowest range of 
PWV values in comparison with remaining groups.
The results of amplification index measurements 
were presented in Table V. Statistically significant 
difference was found between Marfan syndrome 
and marfanoid groups and between Marfan group 
and control group. The highest average value of 
AI was presented in a  group with Marfan syn-
drome and the lowest average value was obtained 
in a  group with marfanoid phenotype. However, 
in marfanoid group the range of AI values was very 
wide (Table VI). 
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Discussion 
The results of the research prove previously demon-
strated principle that due to altered structure of 
the elastic fibers, arterial walls among patients with 
Marfan syndrome have reduced susceptibility thus 
increased stiffness [5–9, 11, 17, 22]. This expresses 
in increased pulse wave velocity in comparison to 
healthy controls and to patients representing mar-
fanoid phenotype. Mean PWV value was the highest 
amidst patients with Marfan syndrome. After taking 
into account another reference value for PWV mea-
surement [10] given in publication value 6.2 m/s ex-
ceeded 19 patients in Marfan group, which represents 
51.4% of the group. This is at the same time the 
highest percentage of values exceeding reference val-
ue. It can be considered as probable that PWV among 
these patients would subsequently increase over time. 
Finally the majority of them will most likely exceed 
the reference value deriving from European Society of 
Hypertension (ESH) recommendations — 10 m/s, 
which was previously recognized as a sign of increased 
cardiovascular risk and presence of subclinical organ 
damage deriving from hypertension [10, 14, 15]. 
Considering this patients with Marfan syndrome 
should be involved in periodic examinations aiming 
to assess PWV value [20]. The gold standard for this 
according to ESH is the assessment of carotid-femoral 
pulse wave velocity by applanation tonometry [15].
In conducted analysis the PWV values obtained in 
the marfanoid phenotype group were lower than the 
values received in Marfan group and also in control 
group. It applies to both average and median value of 
PWV. Statistically significant difference was found in 
both PWV and AI values between patients with Mar-
fan syndrome and marfanoid phenotype. It indicates 
significantly more frequent occurrence of increased 
arterial stiffness among patients fulfilling diagnostic 
criteria for this syndrome. 
In this study patients with marfanoid phenotype 
were characterized by the lowest values of systolic 
and diastolic blood pressure and the lowest value 
of pulse pressure. It suggests low degree of systolic 
blood pressure augmentation deriving from pulse 
wave return. In control group obtained peripheral 
blood pressure values were different — both systolic 
and diastolic blood pressure were higher than in 
marfanoid group, but similar to values obtained in 
Marfan group.
Another factor describing arterial stiffness is an 
amplification index [11, 12, 14, 16, 17]. According 
to research, it strongly correlates with the value of 
PWV. It reflects the percentage of increase or de-
crease in aortic stiffness in result of arrival of the 
waves reflected on the circuit to the heart. As a result 
of calculation method, this factor is independent of 
blood pressure [12]. In our analysis, AI in a group 
with patients with Marfan syndrome was significant-
ly higher than in the other group. This proves higher 
amplification pressure than in other groups in a mo-
ment of ventricular contraction this demonstrates 
that higher ventricular pressure during ventricular 
contraction and higher disturbance of ventricular 
wall properties in response to reflected wave is high-
er than in other groups. The mean value obtained 
in patients with Marfan syndrome is negative. The 
range of results received in this group was wide. In 
addition, among 37 patients in this group, positive 
AI values were obtained in 14 patients, representing 
37.8% of the group, compared with 14.3% in the 
marfanoid group and 19.4% in the control group.
This shows the highest incidence of haemodynami-
cally disadvantageous situation — too early return 
of reflected wave in group with patient with Marfan 
syndrome. In the group of patients with marfanoid 
phenotype, the amplification coefficient assumed 
a wide range of values, with the most negative mean 
of all results and the smallest proportion of patients 
receiving a positive value. This indicates the most fa-
vorable hemodynamic conditions among all studied 
patient groups [14]. The AI reference values have not 
yet been determined. It can therefore be assumed that 
in our study in a group with patients with marfanoid 
phenotype, the obtained values of the central pressure 
amplification index showed lower arterial stiffness 
than those of Marfan syndrome and control patients.
PWV measurement methods are constrained by 
operator dependency and poor reproducibility of 
results [12, 13]. The value of PWV and AI is influ-
enced by a number of other factors, height, gender, 
Table VI. P values for AI results in each group
Marfan syndrome Marfanoid phenotype Control group
Marfan syndrome — 0.0030 0.0071
Marfanoid phenotype 0.0030 — NS
Control group 0.0071 NS —
NS — non significant
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blood pressure, vascular resistance, ejection volume, 
pulse waveform, heart rate, smoking or vasomotor 
tension. For this reason, and because of the limita-
tions of the statistical analysis resulting from the low 
abundance of the study groups, it would be advisable 
to repeat the PWV and AI measurements on the 
larger groups in terms of abundance.
The obtained results suggest that patients with 
marfanoid phenotype have better arterial suscepti-
bility both from patients with Marfan syndrome and 
those in the control group. Marfanoid patients draw 
the attention of their physician with their distinctive 
appearance — tall, slim figure and phenotypic fea-
tures reminiscent of patients with Marfan syndrome 
[1, 2, 4]. Despite this, they have better haemody-
namic parameters than patients from other groups. 
This is probably due to their higher growth and lower 
BMI (body mass index) relative to the rest of the 
population while maintaining a normal histological 
structure of the arterial walls [21].
Conclusions
Patients with Marfan syndrome have higher vascu-
lar stiffness, which is expressed by higher pulse wave 
velocity and higher central pressure augmentation 
index than in patients with marfanoid phenotype 
and in the control group.
In patients with marfanoid phenotype, the lowest 
values of systolic and diastolic blood pressure and 
pulse pressure were observed. Both the pulse wave 
velocity and the amplification factor in this group 
were among the lowest among all subjects.
It would be advisable to carry out a study in a larg-
er group of patients with a marfanoid phenotype to 
confirm the observed haemodynamic properties in 
this population.
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